Product Overview
[Drug Name]
Generic Name: Lansoprazole Capsules
Trade Name: Nan Guo Chun Lansoprazole Capsules 30mg*10s
Pinyin Code: NanGuoChun LanSuoLaZuoJiaoNang 30mg*10s
[Main Ingredient]
The main ingredient of this product is lansoprazole. Chemical Name: 2-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
[Properties]
This product is a capsule containing white or off-white enteric-coated spherical granules.
[Indications/Main Functions]
Gastric ulcer, duodenal ulcer, reflux esophagitis, Zollinger-Ellison syndrome.
[Specifications]
30mg*10s
[Dosage and Administration]
Adults should typically take 30mg of lansoprazole enteric-coated capsules orally once daily. For duodenal ulcers, take the drug continuously for 4-6 weeks. For gastric ulcers, reflux esophagitis, and Zollinger-Ellison syndrome, take the drug continuously for 6-8 weeks, or as directed by a physician.
[Adverse Reactions]
1. Hypersensitivity: Occasionally, symptoms such as rash and itching may occur. Discontinue use if these symptoms occur. 2. Liver: Occasionally, elevated levels of GOT, GPT, AL-P, LDH, and γ-GTP may occur. Careful observation is required. If any abnormalities are detected, appropriate measures such as discontinuation of the drug should be taken. 3. Blood: Occasionally, symptoms such as anemia, leukopenia, and eosinophilia may occur. Thrombocytopenia is rare. 4. Digestive System: Occasionally, symptoms such as constipation, diarrhea, thirst, and abdominal distension may occur. 5. Neuropsychiatric: Occasionally, symptoms such as headache and drowsiness may occur. Insomnia and dizziness are rare. 6. Other: Occasionally, fever, elevated total cholesterol, and elevated uric acid may occur.
[Contraindications]
This product is contraindicated in patients with allergies.
[Drug Interactions]
It will delay the metabolism and excretion of diazepam and phenytoin. The data has been published in the report of the similar drug omeprazole.
[Precautions]
1. Careful observation should be made during treatment. Due to insufficient experience in long-term use, it is not recommended for maintenance treatment. 2. Do not chew this product when taking it. Swallow the whole tablet with water. 3. Use with caution in the following patients: (1) Patients with a history of drug allergies; (2) Patients with liver and kidney dysfunction. 4. Because this drug can mask the symptoms of gastric cancer, gastric cancer must be ruled out before use.
[Children's Use]
The safety of this drug for children has not been established (due to the limited clinical experience in children).
[Elderly Patients' Use]
Generally speaking, the gastric acid secretion capacity and other physiological functions of elderly patients are reduced, so careful observation should be made during the medication period.
[Overdose]
Not yet clear.
[Pharmacology and Toxicology]
After translocating to the acid-secreting tubules of gastric mucosal parietal cells, this drug transforms into an active form under acidic conditions. This active form binds to the SH group of the proton pump ((H++K+)-ATPase), inhibiting the enzyme's activity and thus inhibiting gastric acid secretion. 1. (H++K+)-ATPase Activity Inhibition: Lansoprazole inhibits (H++K+)-ATPase activity in dog gastric mucosal microsomes (in vitro). 2. Parietal Cell Acid Production Inhibition: Lansoprazole inhibits acid secretion in isolated dog gastric mucosal parietal cells stimulated by histamine, acetylcholine, and gastrin (in vitro). 3. Gastric Acid Secretion Inhibition: 1) Gastrin-Induced Acid Secretion: In healthy adults, oral administration of 30 mg of lansoprazole once daily for 7 consecutive days significantly inhibits gastrin-induced acid secretion, and this effect persists for 24 hours. 2) Insulin-stimulated acid secretion: In healthy adults, oral administration of lansoprazole 30 mg once daily for 7 consecutive days significantly inhibits insulin-induced acid secretion. 3) Nocturnal acid secretion: In healthy adults, oral administration of lansoprazole 30 mg once daily for 7 consecutive days significantly inhibits nocturnal gastric acid secretion. 4) 24-hour acid secretion: In a 24-hour gastric fluid sampling test in healthy adults, oral administration of lansoprazole 30 mg once daily for 7 consecutive days significantly inhibited 24-hour gastric acid secretion. 5) 24-hour gastric pH monitoring: In healthy adults and patients with duodenal ulcers, oral administration of lansoprazole 30 mg once daily for 7 consecutive days significantly inhibited 24-hour gastric acid secretion. 6) 24-Hour Lower Esophageal pH Monitoring: In patients with reflux esophagitis, oral administration of lansoprazole 30 mg once daily for 7 to 9 consecutive days significantly inhibited gastroesophageal reflux. 7) Gastric Acid Secretion in Rats and Gastric Pouch Dogs: This drug significantly and persistently inhibited basal acid secretion in rats and acid secretion induced by histamine, gastrin, carbamylcholine, 2-deoxy-D-glucose, or water immersion stress (in the duodenum). This drug also significantly and persistently inhibited acid secretion in gastric pouch dogs induced by various stimuli, demonstrating stable inhibitory effects during repeated dosing (oral administration). 4. Promoting the Healing of Chronic Ulcers: In rat experiments, lansoprazole significantly promoted the healing of chronic gastric and duodenal ulcers induced by acetic acid (oral administration). 5. Inhibitory effect on ulcer formation: In experiments on rats, it has a significant inhibitory effect (oral or intraduodenal administration) on gastric ulcers caused by water immersion stress test, aspirin or ethanol, duodenal ulcers caused by mepirisl or cysteamine, and reflux esophagitis.
